From breakthrough to blockbuster: the business of biotechnology
From Breakthrough to Blockbuster: The Business of Biotechnology tells the astonishing story of how the biotech industry grew to thousands of small companies around the world, competing with the major pharmaceutical companies that had dominated for a century, and how academic research, venture capita...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Oxford
Oxford University Press
2022
|
| Schlagworte: | |
| Online-Zugang: | DE-2070s Volltext |
| Zusammenfassung: | From Breakthrough to Blockbuster: The Business of Biotechnology tells the astonishing story of how the biotech industry grew to thousands of small companies around the world, competing with the major pharmaceutical companies that had dominated for a century, and how academic research, venture capital, and contract research organizations worked together to support them |
| Beschreibung: | 1 Online-Ressource (241 Seiten) |
| ISBN: | 9780197626306 9780197626313 |
| DOI: | 10.1093/oso/9780195084009.001.0001 |
Internformat
MARC
| LEADER | 00000nmm a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV048410506 | ||
| 003 | DE-604 | ||
| 005 | 20230713 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220816s2022 |||| o||u| ||||||eng d | ||
| 020 | |a 9780197626306 |q (electronic bk.) |9 9780197626306 | ||
| 020 | |a 9780197626313 |9 9780197626313 | ||
| 024 | 7 | |a 10.1093/oso/9780195084009.001.0001 |2 doi | |
| 035 | |a (ZDB-30-PQE)EBC6876552 | ||
| 035 | |a (ZDB-30-PAD)EBC6876552 | ||
| 035 | |a (ZDB-89-EBL)EBL6876552 | ||
| 035 | |a (OCoLC)1274229441 | ||
| 035 | |a (DE-599)BVBBV048410506 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-2070s |a DE-83 | ||
| 084 | |a QR 525 |0 (DE-625)142044: |2 rvk | ||
| 100 | 1 | |a Drakeman, Donald L. |4 aut | |
| 245 | 1 | 0 | |a From breakthrough to blockbuster |b the business of biotechnology |
| 264 | 1 | |a Oxford |b Oxford University Press |c 2022 | |
| 264 | 4 | |c ©2022 | |
| 300 | |a 1 Online-Ressource (241 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 505 | 8 | |a Cover -- From Breakthrough to Blockbuster -- Copyright -- Contents -- List of Figures and Tables -- Preface -- About the Authors -- 1. Following the Map of the Genome -- 2. The Molecules -- 3. The Costly Drug Development Process -- 4. The Companies -- 5. Biotech-Pharma Alliances -- 6. The Biotech Entrepreneur -- 7. The Biotech Industry Track Record -- 8. The Future of the Biotech Industry -- Appendix 1: A COVID-19 Manhattan Project? -- Appendix 2: Renovation as Innovation-Is Repurposing the Future of Drug Discovery Research? -- Bibliography -- Index | |
| 520 | 3 | |a From Breakthrough to Blockbuster: The Business of Biotechnology tells the astonishing story of how the biotech industry grew to thousands of small companies around the world, competing with the major pharmaceutical companies that had dominated for a century, and how academic research, venture capital, and contract research organizations worked together to support them | |
| 650 | 0 | 7 | |a Pharmazeutische Technologie |0 (DE-588)4045699-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Biotechnologie |0 (DE-588)4069491-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Biotechnologische Industrie |0 (DE-588)4208106-3 |2 gnd |9 rswk-swf |
| 653 | 6 | |a Electronic books | |
| 689 | 0 | 0 | |a Biotechnologie |0 (DE-588)4069491-4 |D s |
| 689 | 0 | 1 | |a Pharmazeutische Technologie |0 (DE-588)4045699-7 |D s |
| 689 | 0 | 2 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Biotechnologische Industrie |0 (DE-588)4208106-3 |D s |
| 689 | 1 | 1 | |a Pharmazeutische Technologie |0 (DE-588)4045699-7 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Drakeman, Lisa N. |4 aut | |
| 700 | 1 | |a Oraiopoulos, Nektarios |4 aut | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Drakeman, Donald L. |t From Breakthrough to Blockbuster |d Oxford : Oxford University Press USA - OSO,c2022 |z 9780195084009 |
| 856 | 4 | 0 | |u https://doi.org/10.1093/oso/9780195084009.001.0001 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-30-PQE |a ZDB-28-OSD | ||
| 966 | e | |u https://ebookcentral.proquest.com/lib/hwr/detail.action?docID=6876552 |l DE-2070s |p ZDB-30-PQE |q HWR_PDA_PQE |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1805069575791837184 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Drakeman, Donald L. Drakeman, Lisa N. Oraiopoulos, Nektarios |
| author_facet | Drakeman, Donald L. Drakeman, Lisa N. Oraiopoulos, Nektarios |
| author_role | aut aut aut |
| author_sort | Drakeman, Donald L. |
| author_variant | d l d dl dld l n d ln lnd n o no |
| building | Verbundindex |
| bvnumber | BV048410506 |
| classification_rvk | QR 525 |
| collection | ZDB-30-PQE ZDB-28-OSD |
| contents | Cover -- From Breakthrough to Blockbuster -- Copyright -- Contents -- List of Figures and Tables -- Preface -- About the Authors -- 1. Following the Map of the Genome -- 2. The Molecules -- 3. The Costly Drug Development Process -- 4. The Companies -- 5. Biotech-Pharma Alliances -- 6. The Biotech Entrepreneur -- 7. The Biotech Industry Track Record -- 8. The Future of the Biotech Industry -- Appendix 1: A COVID-19 Manhattan Project? -- Appendix 2: Renovation as Innovation-Is Repurposing the Future of Drug Discovery Research? -- Bibliography -- Index |
| ctrlnum | (ZDB-30-PQE)EBC6876552 (ZDB-30-PAD)EBC6876552 (ZDB-89-EBL)EBL6876552 (OCoLC)1274229441 (DE-599)BVBBV048410506 |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1093/oso/9780195084009.001.0001 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nmm a2200000 c 4500</leader><controlfield tag="001">BV048410506</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20230713</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220816s2022 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780197626306</subfield><subfield code="q">(electronic bk.)</subfield><subfield code="9">9780197626306</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780197626313</subfield><subfield code="9">9780197626313</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1093/oso/9780195084009.001.0001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PQE)EBC6876552</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PAD)EBC6876552</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-89-EBL)EBL6876552</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1274229441</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV048410506</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-2070s</subfield><subfield code="a">DE-83</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QR 525</subfield><subfield code="0">(DE-625)142044:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Drakeman, Donald L.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">From breakthrough to blockbuster</subfield><subfield code="b">the business of biotechnology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford</subfield><subfield code="b">Oxford University Press</subfield><subfield code="c">2022</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (241 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Cover -- From Breakthrough to Blockbuster -- Copyright -- Contents -- List of Figures and Tables -- Preface -- About the Authors -- 1. Following the Map of the Genome -- 2. The Molecules -- 3. The Costly Drug Development Process -- 4. The Companies -- 5. Biotech-Pharma Alliances -- 6. The Biotech Entrepreneur -- 7. The Biotech Industry Track Record -- 8. The Future of the Biotech Industry -- Appendix 1: A COVID-19 Manhattan Project? -- Appendix 2: Renovation as Innovation-Is Repurposing the Future of Drug Discovery Research? -- Bibliography -- Index</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">From Breakthrough to Blockbuster: The Business of Biotechnology tells the astonishing story of how the biotech industry grew to thousands of small companies around the world, competing with the major pharmaceutical companies that had dominated for a century, and how academic research, venture capital, and contract research organizations worked together to support them</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Technologie</subfield><subfield code="0">(DE-588)4045699-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biotechnologie</subfield><subfield code="0">(DE-588)4069491-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biotechnologische Industrie</subfield><subfield code="0">(DE-588)4208106-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2="6"><subfield code="a">Electronic books</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Biotechnologie</subfield><subfield code="0">(DE-588)4069491-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmazeutische Technologie</subfield><subfield code="0">(DE-588)4045699-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Biotechnologische Industrie</subfield><subfield code="0">(DE-588)4208106-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmazeutische Technologie</subfield><subfield code="0">(DE-588)4045699-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drakeman, Lisa N.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oraiopoulos, Nektarios</subfield><subfield code="4">aut</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Drakeman, Donald L.</subfield><subfield code="t">From Breakthrough to Blockbuster</subfield><subfield code="d">Oxford : Oxford University Press USA - OSO,c2022</subfield><subfield code="z">9780195084009</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1093/oso/9780195084009.001.0001</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PQE</subfield><subfield code="a">ZDB-28-OSD</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://ebookcentral.proquest.com/lib/hwr/detail.action?docID=6876552</subfield><subfield code="l">DE-2070s</subfield><subfield code="p">ZDB-30-PQE</subfield><subfield code="q">HWR_PDA_PQE</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV048410506 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T20:24:42Z |
| indexdate | 2024-07-20T04:08:13Z |
| institution | BVB |
| isbn | 9780197626306 9780197626313 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033788968 |
| oclc_num | 1274229441 |
| open_access_boolean | |
| owner | DE-2070s DE-83 |
| owner_facet | DE-2070s DE-83 |
| physical | 1 Online-Ressource (241 Seiten) |
| psigel | ZDB-30-PQE ZDB-28-OSD ZDB-30-PQE HWR_PDA_PQE |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Oxford University Press |
| record_format | marc |
| spelling | Drakeman, Donald L. aut From breakthrough to blockbuster the business of biotechnology Oxford Oxford University Press 2022 ©2022 1 Online-Ressource (241 Seiten) txt rdacontent c rdamedia cr rdacarrier Cover -- From Breakthrough to Blockbuster -- Copyright -- Contents -- List of Figures and Tables -- Preface -- About the Authors -- 1. Following the Map of the Genome -- 2. The Molecules -- 3. The Costly Drug Development Process -- 4. The Companies -- 5. Biotech-Pharma Alliances -- 6. The Biotech Entrepreneur -- 7. The Biotech Industry Track Record -- 8. The Future of the Biotech Industry -- Appendix 1: A COVID-19 Manhattan Project? -- Appendix 2: Renovation as Innovation-Is Repurposing the Future of Drug Discovery Research? -- Bibliography -- Index From Breakthrough to Blockbuster: The Business of Biotechnology tells the astonishing story of how the biotech industry grew to thousands of small companies around the world, competing with the major pharmaceutical companies that had dominated for a century, and how academic research, venture capital, and contract research organizations worked together to support them Pharmazeutische Technologie (DE-588)4045699-7 gnd rswk-swf Biotechnologie (DE-588)4069491-4 gnd rswk-swf Pharmazeutische Industrie (DE-588)4045696-1 gnd rswk-swf Biotechnologische Industrie (DE-588)4208106-3 gnd rswk-swf Electronic books Biotechnologie (DE-588)4069491-4 s Pharmazeutische Technologie (DE-588)4045699-7 s Pharmazeutische Industrie (DE-588)4045696-1 s DE-604 Biotechnologische Industrie (DE-588)4208106-3 s Drakeman, Lisa N. aut Oraiopoulos, Nektarios aut Erscheint auch als Druck-Ausgabe Drakeman, Donald L. From Breakthrough to Blockbuster Oxford : Oxford University Press USA - OSO,c2022 9780195084009 https://doi.org/10.1093/oso/9780195084009.001.0001 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Drakeman, Donald L. Drakeman, Lisa N. Oraiopoulos, Nektarios From breakthrough to blockbuster the business of biotechnology Cover -- From Breakthrough to Blockbuster -- Copyright -- Contents -- List of Figures and Tables -- Preface -- About the Authors -- 1. Following the Map of the Genome -- 2. The Molecules -- 3. The Costly Drug Development Process -- 4. The Companies -- 5. Biotech-Pharma Alliances -- 6. The Biotech Entrepreneur -- 7. The Biotech Industry Track Record -- 8. The Future of the Biotech Industry -- Appendix 1: A COVID-19 Manhattan Project? -- Appendix 2: Renovation as Innovation-Is Repurposing the Future of Drug Discovery Research? -- Bibliography -- Index Pharmazeutische Technologie (DE-588)4045699-7 gnd Biotechnologie (DE-588)4069491-4 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Biotechnologische Industrie (DE-588)4208106-3 gnd |
| subject_GND | (DE-588)4045699-7 (DE-588)4069491-4 (DE-588)4045696-1 (DE-588)4208106-3 |
| title | From breakthrough to blockbuster the business of biotechnology |
| title_auth | From breakthrough to blockbuster the business of biotechnology |
| title_exact_search | From breakthrough to blockbuster the business of biotechnology |
| title_exact_search_txtP | From breakthrough to blockbuster the business of biotechnology |
| title_full | From breakthrough to blockbuster the business of biotechnology |
| title_fullStr | From breakthrough to blockbuster the business of biotechnology |
| title_full_unstemmed | From breakthrough to blockbuster the business of biotechnology |
| title_short | From breakthrough to blockbuster |
| title_sort | from breakthrough to blockbuster the business of biotechnology |
| title_sub | the business of biotechnology |
| topic | Pharmazeutische Technologie (DE-588)4045699-7 gnd Biotechnologie (DE-588)4069491-4 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Biotechnologische Industrie (DE-588)4208106-3 gnd |
| topic_facet | Pharmazeutische Technologie Biotechnologie Pharmazeutische Industrie Biotechnologische Industrie |
| url | https://doi.org/10.1093/oso/9780195084009.001.0001 |
| work_keys_str_mv | AT drakemandonaldl frombreakthroughtoblockbusterthebusinessofbiotechnology AT drakemanlisan frombreakthroughtoblockbusterthebusinessofbiotechnology AT oraiopoulosnektarios frombreakthroughtoblockbusterthebusinessofbiotechnology |